S&P 500   4,550.71 (+0.01%)
DOW   35,415.62 (+0.23%)
QQQ   389.07 (-0.03%)
AAPL   189.91 (+0.06%)
MSFT   381.03 (+0.64%)
META   336.56 (+0.56%)
GOOGL   136.64 (+0.17%)
AMZN   146.91 (-0.56%)
TSLA   245.44 (+3.96%)
NVDA   476.18 (-1.29%)
NIO   7.18 (-0.14%)
BABA   76.25 (-1.65%)
AMD   121.74 (-0.74%)
T   16.13 (-0.49%)
F   10.35 (+0.10%)
MU   75.25 (-2.92%)
CGC   0.53 (-2.74%)
GE   119.04 (-0.78%)
DIS   93.13 (-2.14%)
AMC   6.61 (-2.79%)
PFE   29.67 (-1.56%)
PYPL   58.32 (+3.42%)
XOM   104.22 (+0.25%)
S&P 500   4,550.71 (+0.01%)
DOW   35,415.62 (+0.23%)
QQQ   389.07 (-0.03%)
AAPL   189.91 (+0.06%)
MSFT   381.03 (+0.64%)
META   336.56 (+0.56%)
GOOGL   136.64 (+0.17%)
AMZN   146.91 (-0.56%)
TSLA   245.44 (+3.96%)
NVDA   476.18 (-1.29%)
NIO   7.18 (-0.14%)
BABA   76.25 (-1.65%)
AMD   121.74 (-0.74%)
T   16.13 (-0.49%)
F   10.35 (+0.10%)
MU   75.25 (-2.92%)
CGC   0.53 (-2.74%)
GE   119.04 (-0.78%)
DIS   93.13 (-2.14%)
AMC   6.61 (-2.79%)
PFE   29.67 (-1.56%)
PYPL   58.32 (+3.42%)
XOM   104.22 (+0.25%)
S&P 500   4,550.71 (+0.01%)
DOW   35,415.62 (+0.23%)
QQQ   389.07 (-0.03%)
AAPL   189.91 (+0.06%)
MSFT   381.03 (+0.64%)
META   336.56 (+0.56%)
GOOGL   136.64 (+0.17%)
AMZN   146.91 (-0.56%)
TSLA   245.44 (+3.96%)
NVDA   476.18 (-1.29%)
NIO   7.18 (-0.14%)
BABA   76.25 (-1.65%)
AMD   121.74 (-0.74%)
T   16.13 (-0.49%)
F   10.35 (+0.10%)
MU   75.25 (-2.92%)
CGC   0.53 (-2.74%)
GE   119.04 (-0.78%)
DIS   93.13 (-2.14%)
AMC   6.61 (-2.79%)
PFE   29.67 (-1.56%)
PYPL   58.32 (+3.42%)
XOM   104.22 (+0.25%)
S&P 500   4,550.71 (+0.01%)
DOW   35,415.62 (+0.23%)
QQQ   389.07 (-0.03%)
AAPL   189.91 (+0.06%)
MSFT   381.03 (+0.64%)
META   336.56 (+0.56%)
GOOGL   136.64 (+0.17%)
AMZN   146.91 (-0.56%)
TSLA   245.44 (+3.96%)
NVDA   476.18 (-1.29%)
NIO   7.18 (-0.14%)
BABA   76.25 (-1.65%)
AMD   121.74 (-0.74%)
T   16.13 (-0.49%)
F   10.35 (+0.10%)
MU   75.25 (-2.92%)
CGC   0.53 (-2.74%)
GE   119.04 (-0.78%)
DIS   93.13 (-2.14%)
AMC   6.61 (-2.79%)
PFE   29.67 (-1.56%)
PYPL   58.32 (+3.42%)
XOM   104.22 (+0.25%)

Harrow Health Stock Price, News & Analysis (NASDAQ:HROW)

$9.06
-0.04 (-0.44%)
(As of 02:27 PM ET)
Compare
Today's Range
$8.72
$9.06
50-Day Range
$8.10
$16.36
52-Week Range
$7.60
$28.25
Volume
251,085 shs
Average Volume
520,237 shs
Market Capitalization
$318.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.80

Harrow Health MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
330.6% Upside
$38.80 Price Target
Short Interest
Bearish
17.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Harrow Health in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$266,174 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.43) to $0.40 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

594th out of 935 stocks

Pharmaceutical Preparations Industry

279th out of 435 stocks


HROW stock logo

About Harrow Health Stock (NASDAQ:HROW)

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

HROW Stock Price History

HROW Stock News Headlines

HROWM Harrow Health, Inc. NT CAL 27
Harrow to Present at Two Investor Conferences in November
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Harrow Recent Insider Activity
Why Is Eyecare-Focused Harrow Health Stock Trading Lower Today?
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Harrow Announces Third Quarter 2023 Financial Results
Harrow Inc HROW
Implications Of Harrow's Short-Term Guidance
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
Harrow Health's 5-Year Guidance
Harrow Health (NASDAQ: HROW)
Why Harrow Health Stock Is Trading Higher Today?
Why Shares of Harrow Health Are Jumping Wednesday
See More Headlines
Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HROW
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.80
High Stock Price Target
$45.00
Low Stock Price Target
$34.40
Potential Upside/Downside
+326.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,090,000.00
Pretax Margin
-11.36%

Debt

Sales & Book Value

Annual Sales
$88.60 million
Cash Flow
$0.21 per share
Book Value
$1.01 per share

Miscellaneous

Free Float
30,342,000
Market Cap
$319.59 million
Optionable
Optionable
Beta
0.48
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Mark L. Baum J.D. (Age 49)
    CEO & Chairman
    Comp: $1.07M
  • Mr. Andrew R. Boll C.F.A. (Age 40)
    C.M.A., CFA, CMA, CFO & Corp. Sec.
    Comp: $716.73k
  • Dr. Robert J. Kammer D.D.S. (Age 73)
    Special Advisor
    Comp: $91.88k
  • Mr. John P. Saharek MBA (Age 62)
    Chief Commercial Officer
    Comp: $621.92k
  • Jamie Webb
    Director of Communications & Investor Relations
  • Dr. Dennis E Saadeh Pharm.D.
    Chief of Formulation Strategy
  • Mr. Andrew Livingston
    Chief Innovation Officer
  • Ms. Kim Barratt
    Chief Talent Officer














HROW Stock Analysis - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares.
View HROW analyst ratings
or view top-rated stocks.

What is Harrow Health's stock price target for 2024?

2 brokers have issued 1-year target prices for Harrow Health's stock. Their HROW share price targets range from $34.40 to $45.00. On average, they predict the company's share price to reach $38.80 in the next year. This suggests a possible upside of 330.2% from the stock's current price.
View analysts price targets for HROW
or view top-rated stocks among Wall Street analysts.

How have HROW shares performed in 2023?

Harrow Health's stock was trading at $14.76 at the beginning of the year. Since then, HROW shares have decreased by 38.9% and is now trading at $9.02.
View the best growth stocks for 2023 here
.

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our HROW earnings forecast
.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) posted its earnings results on Monday, November, 13th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.12. The company earned $34.27 million during the quarter, compared to analyst estimates of $37.58 million. Harrow Health had a negative net margin of 12.44% and a negative trailing twelve-month return on equity of 6.55%. The business's quarterly revenue was up 50.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) EPS.

What ETFs hold Harrow Health's stock?

ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Jacob Forward ETF (JFWD) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has Harrow Health issued on next quarter's earnings?

Harrow Health issued an update on its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $129.00 million-$136.00 million, compared to the consensus revenue estimate of $141.53 million.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (5.15%), Morgan Stanley (5.06%), Private Capital Management LLC (4.04%), Invictus Private Wealth LLC (1.14%), Paradigm Capital Management Inc. NY (1.12%) and Stifel Financial Corp (0.97%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends
.

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HROW) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -